Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BOB GENG

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1356570758
CMS profile
288980
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$565,906.48

553 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BOB GENG

NPI 1356570758 · CMS profile ID 288980

Allopathic & Osteopathic Physicians / Allergy & Immunology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BOB GENG, NPI 1356570758, CMS profile ID 288980. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BOB GENG, NPI 1356570758, CMS profile ID 288980. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BOB GENG, NPI 1356570758, CMS profile ID 288980, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

553 matching records · $565,906.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 553 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 553.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BioCryst US Sales Co., LLC $485.7911/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117480060 CMS
BioCryst US Sales Co., LLC $124.9911/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117480884 CMS
BioCryst US Sales Co., LLC $776.2011/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117474336 CMS
BioCryst US Sales Co., LLC $2,410.1611/11/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117475950 CMS
GlaxoSmithKline, LLC. $3,900.0011/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116703866 CMS
Takeda Pharmaceuticals U.S.A., Inc. $659.7411/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137553441 CMS
Regeneron Healthcare Solutions, Inc. $2,705.4611/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114054335 CMS
GC Biopharma USA, Inc. $23.0711/05/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155403200 CMS
Pharming Healthcare, Inc. $19.0211/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132148760 CMS
PFIZER INC. $21.6510/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132105714 CMS
Grifols USA, LLC $20.7910/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124734231 CMS
PFIZER INC. $3,000.0010/28/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131623603 CMS
Blueprint Medicines Corporation $55.1810/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147452365 CMS
Novartis Pharmaceuticals Corporation $35.0910/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086906103 CMS
Takeda Pharmaceuticals U.S.A., Inc. $58.3910/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137553439 CMS
Novartis Pharmaceuticals Corporation $90.7110/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086906113 CMS
BioCryst US Sales Co., LLC $75.1310/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117469417 CMS
Regeneron Healthcare Solutions, Inc. $94.4510/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114054333 CMS
ABBVIE INC. $2,875.0010/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103151477 CMS
ABBVIE INC. $2,875.0010/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103151479 CMS
ABBVIE INC. $4,025.0010/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103151481 CMS
ADMA BioManufacturing LLC $7.0010/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149638674 CMS
ADMA BioManufacturing LLC $134.4210/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639566 CMS
GENZYME CORPORATION $25.6210/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828296 CMS
GlaxoSmithKline, LLC. $491.0010/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115980838 CMS
ADMA BioManufacturing LLC $150.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639924 CMS
ADMA BioManufacturing LLC $699.1010/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639926 CMS
ADMA BioManufacturing LLC $1,616.0010/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639928 CMS
ADMA BioManufacturing LLC $635.0010/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639930 CMS
ADMA BioManufacturing LLC $5,000.0010/17/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149639932 CMS
Pharming Healthcare, Inc. $13.8410/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132148755 CMS
GENZYME CORPORATION $2,399.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828316 CMS
GENZYME CORPORATION $18.9810/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828324 CMS
GENZYME CORPORATION $2,399.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828326 CMS
GlaxoSmithKline, LLC. $3,900.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116377564 CMS
GlaxoSmithKline, LLC. $1,950.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116455225 CMS
GlaxoSmithKline, LLC. $3,900.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116467778 CMS
GlaxoSmithKline, LLC. $3,900.0010/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116727718 CMS
GENZYME CORPORATION $130.3210/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828330 CMS
GENZYME CORPORATION $6,396.0010/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828332 CMS
GENZYME CORPORATION $316.0810/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828334 CMS
GENZYME CORPORATION $749.6710/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828336 CMS
GENZYME CORPORATION $1,764.8910/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828338 CMS
GENZYME CORPORATION $9,812.0010/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139828348 CMS
Pharming Healthcare, Inc. $23.9010/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132148749 CMS
GlaxoSmithKline, LLC. $83.7510/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116099275 CMS
GlaxoSmithKline, LLC. $918.0010/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116531394 CMS
GlaxoSmithKline, LLC. $107.2010/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116557297 CMS
GlaxoSmithKline, LLC. $51.5910/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116634738 CMS
GlaxoSmithKline, LLC. $13.3910/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116724376 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $169,348.85 286
PY2020 $108,166.48 161
PY2021 $339,171.45 401
PY2022 $641,256.55 730
PY2023 $732,138.57 768
PY2024 $565,906.48 553
PY2025 $760,491.09 689

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $33,050.55 6
PY2025 Principal investigator $909,096.20 17
PY2024 Recipient $46,530.00 7
PY2024 Principal investigator $444,485.66 19
PY2023 Recipient $49,420.00 8
PY2023 Principal investigator $634,787.69 14
PY2022 Recipient $6,226.25 3
PY2022 Principal investigator $545,288.26 1
PY2021 Recipient $2,670.00 3
PY2020 Recipient $6,499.28 7
PY2020 Principal investigator $29,930.16 2
PY2019 Recipient $355.10 1
PY2019 Principal investigator $99,839.39 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $46,625.00 12/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER APC
Real World Experience and Pharmacokinetics of IG-Naive Immunodeficiency Patients Starting Cuvitru No dispute reported 06/30/2026 1223289702
Principal investigator 1 GENZYME CORPORATION $43,813.00 11/10/2025 Non-covered Recipient Entity
Allergy And Asthma Medical Group And Research Center, Apc
Mechanism of Action and Immunomodulatory Effects of Dupilumab on Chronic Rhinosinusitis with Nasal Polyposis No dispute reported 06/30/2026 1226145362
Principal investigator 1 Lilly USA, LLC $25,000.00 11/03/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA MEDICAL GROUP AND RESEARCH CENTER APC
Not supplied No dispute reported 06/30/2026 1187872539
Principal investigator 1 Amgen Inc. $15,629.21 10/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246638959
Recipient LEO Pharma Inc. $25,000.00 10/15/2025 Covered Recipient Physician CHARACTERIZATION OF UNMET NEED FOR TARGETED PRECISION MEDICATION IN ATOPIC DERMATITIS DUE TO INADEQUATE OR POOR RESPONSE TO DUPILUMAB No dispute reported 06/30/2026 1251994446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56,100.00 09/30/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA MEDICAL GROUP AND RESEARCH CENTER
A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged =6 to <18 Years With Atopic Dermatitis No dispute reported 06/30/2026 1184244419
Recipient Amgen Inc. $2,030.55 09/22/2025 Covered Recipient Physician A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) No dispute reported 06/30/2026 1246636966
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,869.00 08/28/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER, APC
A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON No dispute reported 06/30/2026 1185553924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28,050.00 07/29/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA MEDICAL GROUP AND RESEARCH CENTER
A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged =6 to <18 Years With Atopic Dermatitis No dispute reported 06/30/2026 1184221354
Principal investigator 1 GENZYME CORPORATION $345,249.18 06/05/2025 Non-covered Recipient Entity
Allergy And Asthma Medical Group And Research Center, Apc
ORIGINS: Deciphering the immunopathogenesis of atopic dermatitis, using spatial single-cell transcriptomics to identify key pathways and targetable mediators involved in the disease trajectory No dispute reported 06/30/2026 1226145326
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,151.00 05/09/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185553928
Principal investigator 1 Incyte Corporation $32,700.00 05/07/2025 Non-covered Recipient Entity
Allergy & Asthma Medical Grp and Rch Ctr
A Quality Improvement Study - Assessing Total Steroid Burden for Patients with Atopic Dermatitis No dispute reported 06/30/2026 1240501637
Principal investigator 1 Incyte Corporation $32,700.00 05/07/2025 Non-covered Recipient Entity
Allergy & Asthma Medical Grp and Rch Ctr
A Quality Improvement Study - Assessing Total Steroid Burden for Patients with Atopic Dermatitis No dispute reported 06/30/2026 1240501641
Recipient PFIZER INC. $3,200.00 04/26/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228828987
Principal investigator 1 Grifols Shared Services North America, Inc. $21,000.00 04/23/2025 Non-covered Recipient Entity
Allergy And Asthma Medical Group And Research Center, Apc
Chronic Rhinosinusitis without Nasal Polyps Screening and Prospective Testing No dispute reported 06/30/2026 1244167845
Principal investigator 1 Eli Lilly and Company $1,024.95 03/20/2025 Non-covered Recipient Entity
MEETING PROTOCOL WORLDWIDE LP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187884934
Principal investigator 1 AstraZeneca Pharmaceuticals LP $97,721.85 03/07/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL No dispute reported 06/30/2026 1185553926
Recipient PFIZER INC. $940.00 03/07/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228828404
Recipient PFIZER INC. $940.00 01/30/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228828981
Recipient PFIZER INC. $940.00 01/30/2025 Covered Recipient Physician ABROCITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228829593
Principal investigator 1 Eli Lilly and Company $49,588.03 01/15/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187880647
Principal investigator 1 AstraZeneca Pharmaceuticals LP $85,638.53 01/03/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185553922
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,236.45 01/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled No dispute reported 06/30/2026 1190309740